AKT1 and lung carcinoma: As shown in Figure 2G, GSEA revealed a significant enrichment of the PI3K–AKT signaling pathway in lung cancer (NES = 1.786; p < 0.001; FDR < 0.001), a finding that is consistent with the predictions of the network pharmacology analysis.